CONMED stock
CNMDNYSECONMED Corporation, HealthcareISIN US2074101013
68Score 68 out of 100, Neutral
Price and trend
89 / 100
Price history
+16% in one yearThe chart shows daily closes over 20 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Above the 200-day line: the price is 21% above it.
Since August 2026 the 50-day line has been above the 200-day line; the trend has turned up.
Normal: the price is neither overheated nor sold off (RSI 53).
The price is 5.9% below its 52-week high. Largest decline in 20 years: 80% (November 2021 to June 2026).
Chart figures for advanced users
- SMA 50$47.14
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$41.84
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)53
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDabove the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$32.11
- The lowest closing price of the last twelve months.
- Resistance$53.66
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- CONMED Corporation belongs to the Medical (Devices) industry (United States) and, with a market value of $1.5B, is number 48 of 88 companies in its industry on MEQIRI.
- In fiscal 2025 it reported revenue of $1.37B (up 5.2% year on year) and earnings of $47.06M (down 64.5%).
- For fiscal 2026, analysts expect on average revenue of $1.36B (down 0.9%) and adjusted earnings per share of $4.57 (down 0.8%).
Show more
- MEQIRI Score 68 out of 100 (Neutral): rank 162 of 702 in Healthcare, median 53.
- The P/E is 20.7 (Medical (Devices) median 29.1, own median of recent years 48.2).
- Our model puts fair value at $72.27, with the price 30% below it.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- Earnings per share growingUp 35.7% a year since 2020.Growth 83
- Earnings turn into cashFree cash flow 181% of earnings over the last 12 months.Fundamentals 80
- Below fair valuePrice 30% below the fair value of $72.27.Valuation 68
Weaknesses
- Volatile share priceVolatility 47% a year over the last 12 months.Stability 57
Its standout strengths are technical analysis and growth, while profitability and capital allocation hold the score back.
Daily figure as of 13 Nov 2026
How the score is calculatedScore overview
Score since yesterday from 69 to 68.
Fundamentals are strong, with stable profits and strong cash generation.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansCrash risk medium
How well MEQIRI warnsIn the middle among smaller stocks.
From 2016 to 2025, 20 in 100 such stocks fell 30% or more within a year, against a group average of 23 in 100.
What drives the risk
- high price swings
- high growth grade (crashed more often in the backtest)
What lowers it
- price near its 52-week high
- solid fundamentals
Valuation
Valuation signal
Significantly undervaluedIn our model the price counts as cheap below $51.62 and expensive above $120.44 (uncertainty high, based on the price swings of the past year).
The two parts of the fair value come to $73.69 (cash-flow model) and $70.84 (industry comparison), and the gap between them shows how uncertain the estimate is. The price is below both.
Calculated with a cost of equity of 10.1%. At 11.1% the fair value would be $67.25, at 9.1% it would be $79.17.
Valuation metrics
Half from the cash-flow model, half from earnings times the industry P/E (29.1).
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In the twelve months to 30 Sep 2026, revenue rose 1.7% on the twelve months before. Revenue has grown solidly since 2006, at about 4% per year.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 53%, operating 10%, net 3%.
Debt & balance sheet
latest quarterModerate debt, and interest is adequately covered.
Earnings
- Next earnings
- 27 Jan 2027in 75 days
- Last reported
- 28 Oct 2026EPS reported $1.04 (expected $1.00)above expectations
Analyst estimates
Earnings estimates have barely changed since 15 Oct 2026.
- Earnings per share
- $4.57+0.8%
- Revenue
- $1.36B−0.3%
- Earnings per share
- $4.75−0.7%
- Revenue
- $1.43B−0.5%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Company outlook mixed
Share price after the results: −3.1%CONMED slightly raised its 2026 EPS guidance to $4.54 to $4.61 (from $4.48 to $4.60), but lowered the top end of organic sales growth guidance to 5% to 5.5% (from 5% to 6%).
“With respect to profitability guidance for 2026, we now expect non GAAP adjusted diluted earnings per share in the range of $4.54 to $4.61. Compared to our prior guidance range $4.48 to $4.60.”The outlook is not part of the score and not a recommendation to buy or sell.
From the earnings call on 28 Oct 2026 (fiscal Q3 2026), read by AI.
Insiders
Open-market purchases and sales by executives, board members and major holders
No open-market purchases or sales in the last 6 months.
- Glaze RichardSale
21 Nov 2025, Chief Information Officer
- Shares
- 257
- Price
- $41.21
- Value
- $10,591
Source: Form 4 filings with the US Securities and Exchange Commission. Grants, option exercises, gifts and tax withholdings are hidden. Not a recommendation to buy.
What happened at CONMED
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
702 rated companies in Healthcare
- This company
- 68
- Sector median
- 53
Categories against the sector median
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Medical (Devices)
The next larger and next smaller companies by market value
- Inspire Medical SystemsINSP $1.75B52
- Medartis HoldingMED.SW $1.63B55
- EnovisENOV $1.59B45
- VitrolifeVITR.ST $1.57B51
- EL.En.ELN.MI $1.5B75
- Lumexa Imaging HoldingsLMRI $1.44B48
- NovocureNVCR $1.37B29
- PROCEPT BioRoboticsPRCT $1.35B41
ETFs that hold CONMED
Held by 12 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| L&G Healthcare Technology & Innovation UCITS ETFXMLH | 1.32% | 0.49% | €318.64M |
| iShares S&P SmallCap 600 UCITS ETFIUS3 | 0.08% | 0.30% | €2.31B |
| L&G Russell 2000 US Small Cap Quality UCITS ETFETLZ | 0.07% | 0.30% | €185.82M |
Show 5 more
| Xtrackers Russell 2000 UCITS ETF 1CXRS2 | 0.05% | 0.30% | €2.22B |
| State Street SPDR Russell 2000 U.S. Small Cap UCITS ETF (Acc)ZPRR | 0.05% | 0.30% | €4.28B |
| State Street SPDR MSCI USA Small Cap Value Weighted UCITS ETFZPRV | 0.04% | 0.30% | €964.08M |
| State Street SPDR MSCI World Small Cap UCITS ETF (Acc)ZPRS | 0.02% | 0.45% | €1.54B |
| iShares MSCI USA Small Cap CTB Enhanced ESG UCITS ETFSXRG | 0.01% | 0.43% | €2.5B |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Neutral, published since 7 Nov 2026 (in the score history since 31 Mar 2024)
- Valuation signal Undervalued since 7 Nov 2026, previously Fairly valued
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.